The World In A Grain Of Sand
By KdT Ventures
The World In A Grain Of SandApr 19, 2023
The World in a Grain of Sand: Amylyx Pharmaceuticals
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:
the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more
For updates from KdT, please subscribe to our Substack.
The World in a Grain of Sand: Codiak BioSciences
KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Codiak BioSciences.
The World in a Grain of Sand: Royalty Pharma
KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Royalty Pharma.
The World in a Grain of Sand: Sana Biotechnology
KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Sana Biotechnology.
The World in a Grain of Sand: Editas
KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Editas.
The World in a Grain of Sand: Century Therapeutics
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Century Therapeutics.
The World In A Grain of Sand: Taysha
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Taysha GTx
The World In A Grain of Sand: Atai
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Atai
The World In A Grain of Sand: Recursion Pharmaceuticals
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Recursion Pharmaceuticals.
The World In A Grain of Sand: AbCellera
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, AbCellera.